# Your first GLP-1 consultation: what gets reviewed

A first GLP-1 visit covers health history, treatment goals, medication safety, product details and follow-up. A prescription is only one possible outcome.

Canonical: https://velri.co/blog/first-glp1-consult-what-to-expect-plus-size-first-step
Publisher: Velri (https://velri.co/about)
Published: 2026-06-15
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

A first GLP-1 consultation is a review of whether a particular medicine fits your health needs. It should connect your weight history and goals with the expected benefits, possible side effects, other medicines and cost. [1]

You do not need to arrive with a treatment decision already made.

## Your history provides the starting point

The conversation commonly covers previous weight-management efforts, related health conditions, current medicines and family history. Pregnancy plans are also relevant because weight-management medicines are not used during pregnancy. [1]

For semaglutide and tirzepatide, specific safety questions include a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Their approved weight-management labels list these as contraindications. A history of severe stomach-emptying problems, pancreatitis or gallbladder symptoms also belongs in the review. [2][3]

Other prescriptions matter. Some combinations increase the risk of low blood sugar, and tirzepatide has a specific interaction that can reduce the effectiveness of oral hormonal contraceptives. [2][3]

## Know exactly which product is being discussed

The active ingredient, formulation and approval status should be clear. Evidence for an approved product does not automatically establish the same results for a different compounded preparation. Compounded drugs are not FDA approved; the FDA does not review their safety, effectiveness or quality before marketing. [4]

Semaglutide and tirzepatide also have different product instructions. A plan should identify what is prescribed and how questions about administration will be handled. [2][3]

## What follow-up should cover

Nausea, vomiting, diarrhea and constipation are among the common side effects in the approved labels. Persistent or severe symptoms need a response, particularly when vomiting or diarrhea could cause dehydration. [2][3]

Follow-up is also where the treatment's value is reassessed: whether it is helping, whether side effects are acceptable, and whether the expense and routine remain workable. [1]

Before the visit ends, it should be clear who handles questions, how follow-up is arranged, and what the full cost includes. Those practical details help turn a possible prescription into a plan you can evaluate.

## Sources
[1] Prescription Medications to Treat Overweight & Obesity - NIDDK (2025). https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
[2] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[3] DailyMed - ZEPBOUND- tirzepatide injection, solution
ZEPBOUND- tirzepatide injection, solution
ZEPBOUND KWIKPEN- tirzepatide injection, solution (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[4] Compounding and the FDA: Questions and Answers | FDA (2025). https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support